Ross Cheloha @rche54.bsky.social · 07/08/2026John was such an encouraging and thoughtful presence within the NIH IRP. I will dearly miss seeing him in the halls and talking science and/or life. A huge loss 011
Reposted by Ross ChelohaRetro Tech Dreams @retrotechdreams.bsky.social · 14/04/2026Myst (1993) 1344482
Ross Cheloha @rche54.bsky.social · 27/01/2026 Congrats to Shubhra Jyoti Saha on leading this very successful project in the lab, and our collaborators for making this work possible. Many thanks to NIH Office of AIDS Research and the NIH IRP (NIDDK and NIAID) for supporting this work. 000
Ross Cheloha @rche54.bsky.social · 27/01/2026They also retain strong activity against every strain of HIV tested. Such conjugates are even more potent than monoclonal antibodies and fusion inhibitor peptides applied in the clinic. 100
Ross Cheloha @rche54.bsky.social · 27/01/2026This was a collaboration with the Bewley and Doria-Rose labs at NIH IRP. Linking fusion inhibitor peptides, which block HIV viral infection with modest potency, to single domain antibodies for delivery to the cell surface, leads to enormous enhancements in antiviral potency (up to 10,000-fold!) 100
Ross Cheloha @rche54.bsky.social · 27/01/2026My first corresponding author publication in @jacs.acspublications.org Very proud and feeling like a bona fide chemist pubs.acs.org/doi/full/10....pubs.acs.org 270
Reposted by Ross ChelohaJanelia Research Campus @hhmijanelia.bsky.social · 15/12/2025Apply by Feb. 3 to become a Janelia Group Leader! Group Leaders drive breakthroughs & experimental approaches in imaging, molecular engineering, protein chemistry, mass spectrometry, & methods that don't yet exist. Learn more: janelia.org/groupleader 🧪 01821
Reposted by Ross ChelohaJames Checco @jameswchecco.bsky.social · 04/12/2025Consider submitting your peptide research to a special joint issue of JOC and Biochemistry on the Chemistry and Biology of Peptides! axial.acs.org/biology-and-...axial.acs.orgCall For Papers: Chemistry and Biology of Peptides | ACS Publications Chemistry BlogThis Special Issue will celebrate the chemistry and biology of peptides, from synthesis, to structure and modifications, to biology and applications, and finally to degradation. Submit your manuscript... 092
Reposted by Ross ChelohaPLOS Biology @plosbiology.org · 25/11/2025Bitopic ligands comprise a #pharmacophore & a linked moiety that bind to separate sites. @rche54.bsky.social &co show that #GPCRs that bind small molecules can be potently activated by #bitopic #nanobody -ligand conjugates to selectively target pairs of GPCRs @plosbiology.org 🧪 plos.io/4p3VOyH 033
Ross Cheloha @rche54.bsky.social · 22/11/2025It’s really meaningful to have such insightful coverage from a leader in the field @zenbrainest.bsky.social and Xianglin Huang. We appreciate the time they took to write up this very nice commentary! 022
Ross Cheloha @rche54.bsky.social · 22/11/2025So cool to read this commentary that covers our recent work! journals.plos.org/plosbiology/...journals.plos.orgNanobody-drug conjugates for targeting specific GPCR pairsBitopic ligands that engage two distinct binding sites offer exciting opportunities for finely tuned control of G protein-coupled receptor signaling. This Primer explores a recent study in PLOS Biology that reports novel nanobody-small molecule conjugates and demonstrates their logic-gated activity at co-expressed receptor pairs with improved signaling profiles. 141
Ross Cheloha @rche54.bsky.social · 20/11/2025ii. Recognition that these nanobody-ligand conjugated only show activity when both the nanobody AND ligand targets are expressed (logic gated signaling). This should be useful for delivering molecules with widely expressed targets only to cells of choice! Congrats to Shivani Sachdev and Swarnali Roy 130
Ross Cheloha @rche54.bsky.social · 20/11/2025This work described for the first time two new directions we are excited to explore: I. nanobody-small molecule conjugates as a sort of analogue of traditional antibody-drug conjugates but we are targeting GPCRs at the cell surface instead of intracellular targets. 110
Ross Cheloha @rche54.bsky.social · 20/11/2025So pleased to share the final version of this work published in @plosbiology.org ! journals.plos.org/plosbiology/...journals.plos.orgDevelopment of bitopic nanobody-ligand conjugates targeting G protein-coupled receptors and exhibiting logic-gated signalingBitopic ligands are comprised of a pharmacophore and a linked moiety that bind to separate sites. This study shows that G-protein coupled receptors (GPCRs) that bind small molecules can be potently ac... 283
Ross Cheloha @rche54.bsky.social · 03/09/2025Read this in a paper and it was totally new to me (after 18 years in biochemistry research): “Peptides translated from the sense and antisense strands of DNA interact specifically, analogous to the complementary interactions between DNA double strands.” Is this widely studied/actually true?? 🤯 120
Reposted by Ross ChelohaJeremy Baskin @jeremybaskin.bsky.social · 25/08/2025Faculty opening in Cornell Chemistry at the Assistant Professor level in the area of chemical biology, broadly defined! academicjobsonline.org/ajo/jobs/30338 #chemjobsacademicjobsonline.orgCornell University, Chemistry and Chemical Biology Job #AJO30338, WDR-00054776 Assistant Professor - Chemistry and Chemical Biology, Cornell University (Ithaca, NY), Chemistry and Chemical Biology, Cornell University, Ithaca, New York, US 14952
Reposted by Ross ChelohaFanny Chasseloup @fannychasseloup.bsky.social · 17/07/2025Last day at #ENDO2025 was great! Amazing symposium on bone and calcium disorders 🦴 by @rche54.bsky.social @MichailLionakis @MichaelMannstadt with great talks on GPCRs and nanobodies, JAK inhibitors in APECED syndrome & new PTH therapies 🤩 041
Reposted by Ross ChelohaJames Checco @jameswchecco.bsky.social · 23/06/2025This Wednesday and Thursday is the VIRTUAL Nebraska Drug Discovery and Development Pipeline Symposium! Registration is still open! Plenary speakers include Brian Kobilka and Virginia Man-Yee Lee. #chemsky, you should attend! research.unl.edu/blog/annual-...research.unl.eduAnnual Nebraska Drug Discovery and Development Pipeline symposium June 25-26World-renowned experts will offer their insights during the fifth annual ND3P Symposium, set for June 25-26. The symposium will be virtual and highly interactive. 031
Ross Cheloha @rche54.bsky.social · 22/05/2025Check out the final published product in Journal of Biological Chemistry! www.jbc.org/article/S002...jbc.orgEvaluation of Alphafold modeling for elucidation of nanobody-peptide epitope interactionsModels of Ab-antigen complexes can be used to understand interaction mechanisms and for improving affinity. This study evaluates the use of the protein structure prediction algorithm AlphaFold (AF) fo... 010
Reposted by Ross ChelohaGeorge Burslem @gburslem.bsky.social · 01/05/2025Excited to see this out in @science.org today!! www.science.org/doi/10.1126/...science.orgIntracellular protein editing enables incorporation of noncanonical residues in endogenous proteinsThe ability to study proteins in their native cellular context is crucial to our understanding of biology. In this work, we report a technology for intracellular protein editing, drawing from split in... 613552
Reposted by Ross ChelohaFreddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 14/04/2025Next up, a collaboration with Ross Cheloha's group (@rche54 @rche54.bsky.social) and @MitchellHo leveraging a novel self-labeling approach for site-specific modification of nanobodies for biological applications. doi.org/10.1002/advs... 3/5 111
Reposted by Ross ChelohaFreddy E Escorcia, MD/PhD @freddyeescorcia.bsky.social · 14/04/2025It's been a while since I posted on some of the ☢️ #radiopharmaceuticals ☢️ work we've been brewing. Let's fix that... 🧵👇 1/5 141
Reposted by Ross ChelohaJordan Meier @doc-jlmeier.bsky.social · 10/04/2025Great news: NIH postbac program is recruiting again! If your grad school plans were affected by program cutbacks or admissions freezes this year I highly encourage you to apply, this could be a perfect opportunity. Please repost. www.training.nih.gov/research-tra...training.nih.gov 6207195
Reposted by Ross ChelohaCarolyn Bertozzi @carolynbertozzi.bskyverified.social · 26/03/2025Check out our new review on induced proximity modalities (#TPD and a lot more!) aimed cell surface targets @naturebiotech.bsky.social, spearheaded by postdocs Nick Till and "Rahm" Ramanathan www.nature.com/articles/s41...nature.comInduced proximity at the cell surface - Nature BiotechnologyTechnologies to modulate induced proximity at the cell surface advance the manipulation of diverse biological responses. 07922
Reposted by Ross ChelohaAlphaFold Unofficial @alphafold.bsky.social · 20/03/2025The findings suggest that optimizing input parameters and refining competition-based modeling approaches may enhance predictive accuracy for antibody-antigen interactions. Intriguing. 021
Ross Cheloha @rche54.bsky.social · 20/03/2025Finally we compared models of nanobody-epitope to nanobody-antigen complexes. In one case Alphafold produced an accurate model with epitope but failed with antigen! This highlights the potential utility of simplifying Alphafold inputs for generating models with improved accuracies (4/4) 120
Ross Cheloha @rche54.bsky.social · 20/03/2025We further showed that Alphafold could be used in a competition mode to identify peptides that bound nanobody with higher affinity than the wild type epitope peptide. We also used modeling to guide design of a peptide-electrophile conjugate that forms a crosslink with nanobody (3/n) 120
Ross Cheloha @rche54.bsky.social · 20/03/2025We performed modeling of experimentally characterized nanobody-peptide interactions and found that 4/6 models matched experimental data. We also crystallized a new nanobody-peptide complex and showed good concordance between the x-ray structure (my first listing on the pdb!) (2/n) 100
Ross Cheloha @rche54.bsky.social · 20/03/2025Excited to share a preprint covering a collaborative project from my group, the Bewley lab (NIDDK), and the Pierce lab (University of Maryland) describing our first foray into assessing Alphafold for predicting peptide-nanobody interactions (1/n) www.biorxiv.org/content/10.1...biorxiv.orgEvaluation of Alphafold modeling for elucidation of nanobody-peptide epitope interactionsModels of Ab-antigen complexes can be used to understand interaction mechanisms and to improve affinity. This study evaluates the use of the protein structure prediction algorithm AlphaFold (AF) for e... 2121
Ross Cheloha @rche54.bsky.social · 13/03/2025We’re excited to apply this for cell-type specific targeting of gpcrs! Congrats to postdocs Shivani Sachdev and Swarnali Roy on the great work (3/3) 010
Ross Cheloha @rche54.bsky.social · 13/03/2025We also show that the activity of these conjugates is dependent on nanobody binding. This property allows us to make conjugates that act in an “and” logic gated manner-only active if 2 different targets are coexpressed on on a single cell. (2/n) 120
Ross Cheloha @rche54.bsky.social · 13/03/2025Proud to share this work from my group in the intramural research program at NIH! We describe a new kind of conjugate made from a small molecule adenosine analog linked to a GPCR targeting nanobody to make antibody drug conjugates that potently and specifically activate signaling (1/n) 🧪 #chembio 1215
Reposted by Ross ChelohabioRxivpreprint @biorxivpreprint.bsky.social · 12/03/2025Nanobody-based conjugates targeting small molecule-binding GPCRs and exhibiting logic-gated signaling www.biorxiv.org/content/10.1101/202… 021
Ross Cheloha @rche54.bsky.social · 23/02/2025This work was made possible through contributions from experts in multiple fields (chemistry, cancer imaging, antibody discovery) working together! The methods described may be useful for the development of imaging probes to provide diagnostic info on other types of tumors or other diseases (3/3) 020
Ross Cheloha @rche54.bsky.social · 23/02/2025The ability to visualize tumors enables an assessment of whether treatments are working or whether cancer has spread. This imaging requires probes that specifically label cancer cells. We developed a new chemistry for creating probes that label liver cancer tumors. (2/n) 100
Ross Cheloha @rche54.bsky.social · 23/02/2025Proud to share this publication about the development of a new method for visualizing tumors! This work resulted from a close collaboration among 3 groups. (1/n) 🧪@freddyeescorcia.bsky.social advanced.onlinelibrary.wiley.com/doi/10.1002/...advanced.onlinelibrary.wiley.comGeneration of Site‐Specifically Labeled Affinity Reagents via Use of a Self‐Labeling Single Domain AntibodySeveral methods have been used to label antibodies to facilitate visualization of cognate targets. Here, we leverage a new variety of conjugation chemistry, based on a crosslinking nanobody, to label... 140
Ross Cheloha @rche54.bsky.social · 16/01/2025I'm actually related to him (second cousins or so)! Can definitely ID the 90's Huskers fans by their reaction when I share this connection 020
Reposted by Ross ChelohaMatt Hall @cispt2.bsky.social · 15/01/2025Our NCATS research program has a history of collaborating and partnering to get treatments to patients. One of my first goals as SD was to capture and share our success in one place - and here it is! 4 approvals and 56 INDs to date - not bad for 12 years old! ncats.nih.gov/research/our... 163
Reposted by Ross ChelohaJeremy Baskin @jeremybaskin.bsky.social · 14/01/2025Overjoyed and honestly relieved to share a Chem Rev magnum opus from Brian Chen & Julia Li titled Synthetic Lipid Biology! In it, we organize efforts across numerous fields to create, manipulate, and analyze lipids and biomembranes. Check it out! doi.org/10.1021/acs.... #lipidtime #chemsky #chembio 88825
Reposted by Ross ChelohaOlalla Vázquez @olallalab.bsky.social · 26/12/2024🎄Xmas gift!🎁Joint work with #OliverHantschel in @naturecomms.bsky.social 💥! Huge kudos 💪🏼😻 Nina 👩🔬 for leading as 1st author & Frank 👨🏼🔬 for training her like a pro❤️ Small delay😅 -my👵broke her hip🤦🏼♀️-loved ones always come first❤️surgery went good💪🏼🤩Let's celebrate🥳🥂! #ChemBio www.nature.com/articles/s41...nature.comDevelopment of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase - Nature CommunicationsIn this work, the authors develop mirror-image monobodies (Mb) made of D-amino acids against the BCR::ABL1 SH2 domain with high binding affinities. The heterochiral Mb-SH2 structures reveal an unusual... 0306
Reposted by Ross ChelohaPossu Huang Lab @possuhuanglab.bsky.social · 17/12/20241/ In two back-to-back papers, we present our de novo TRACeR platform for targeting MHC-I and MHC-II antigens TRACeR for MHC-I: go.nature.com/4gcLzn5 TRACeR for MHC-II: go.nature.com/4gj5OQk 29129
Ross Cheloha @rche54.bsky.social · 14/12/2024I think antimicrobial peptides would even work fine (don't act via a membrane receptor): pubs.acs.org/doi/10.1021/... Mostly, the immune system would lose nucleic acid sensing TLR responses and the T cell branch of adaptive immunity (and perhaps B cell/antibody maturation from T cell co-stim)pubs.acs.orgRetention of Native Quaternary Structure in Racemic Melittin CrystalsRacemic crystallography has been used to elucidate the secondary and tertiary structures of peptides and small proteins that are recalcitrant to conventional crystallization. It is unclear, however, w... 020
Ross Cheloha @rche54.bsky.social · 12/12/2024A thought provoking scenario: what would happen if "mirror" (reverse chirality) microbe were created and released? The time estimate (10 years) seems long to me as there's been incredible progress in making mirror enzymes. You don't need much of a few mirror enzymes for a self sustaining cascade..🧪science.orgConfronting risks of mirror lifeBroad discussion is needed to chart a path forward. 030